Previous in vitro studies have shown that CD36 participates in cellular fat
ty acid (FA) uptake. In vivo evidence for a physiologic role of CD36 in thi
s process is poor and mostly obtained in animals. To examine the metabolic
role of human CD36, we performed a glucose loading, test for normals (n = 1
6) and subjects with CD36 deficiency, both Type I (n = 5) and Type Il (n =
16). After 30 min, FA levels had fallen by 60.1% in normals but by only 31.
7% in Type II deficiency (P <0.01 vs. normals) and 16.5% in Type I deficien
cy which remained significantly higher than the other two groups out to 2 h
. Further, changes in triglyceride and glucose metabolism were observed in
the both types of CD36 deficiency. Impaired fast FA clearance by muscle and
consequently increased hepatic FA uptake seem to underlie these changes. W
e conclude that human CD36 deficiency causes systemic metabolic changes.